Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
AYTU | US
0.00
0.11%
Healthcare
Biotechnology
30/06/2024
17/10/2024
2.29
2.34
2.36
2.29
Aytu Biopharma Inc. a commercial-stage pharmaceutical company focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company operates into two segments Rx segment and Consumer Health segment. The Rx segment consisting of prescription pharmaceutical products sold through third party wholesalers. The Consumer Health segment which consists of various consumer health products sell directly to consumers. It also offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from six years and older; and Cotempla XR-ODT for the treatment of ADHD in patients from six to seventeen years old. In addition the company provides Karbinal ER for the treatment of seasonal and perennial allergies; and Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency. The company was formerly known as Aytu BioScience Inc. and changed its name to Aytu Biopharma Inc. in March 2021. Aytu Biopharma Inc. was incorporated in 2015 and is headquartered in Englewood Colorado.
View LessLow Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Microcap (<300M USD)
Low negative Beta, possible Low Liquidity (< -0.4)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
39.1%1 month
91.1%3 months
61.4%6 months
51.2%-
9.74
0.50
0.55
0.13
1.14
0.11
-
6.11M
14.08M
14.08M
-
-4.45
-
-41.50
-47.24
10.14
5.33
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
0.33
Range1M
0.74
Range3M
0.76
Rel. volume
0.36
Price X volume
24.72K
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Orgenesis Inc | ORGS | Biotechnology | 3.238 | 15.45M | -4.48% | n/a | -84.02% |
LYRA THERAPEUTICS INC | LYRA | Biotechnology | 0.2328 | 15.24M | -3.08% | n/a | 118.63% |
ImmunoPrecise Antibodies Ltd | IPA | Biotechnology | 0.539 | 15.10M | -3.94% | n/a | 49.00% |
Cara Therapeutics Inc | CARA | Biotechnology | 0.2668 | 15.07M | 0.68% | n/a | 406.66% |
IMNN | IMNN | Biotechnology | 0.9787 | 14.09M | -2.12% | n/a | 37.13% |
Cingulate Inc. Common Stock | CING | Biotechnology | 4.49 | 13.67M | 2.05% | n/a | 10.72% |
NRXP | NRXP | Biotechnology | 1.265 | 13.60M | 2.85% | n/a | -46.73% |
Tenax Therapeutics Inc | TENX | Biotechnology | 3.9 | 13.60M | 2.63% | n/a | 3.14% |
Apollomics Inc. Class A Ordinary Shares | APLM | Biotechnology | 0.1232 | 13.55M | -1.36% | n/a | 21.43% |
Edesa Biotech Inc | EDSA | Biotechnology | 4.1 | 13.42M | 0.74% | n/a | 1.35% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Antelope Enterprise Holdings Limited | AEHL | Building Products & Equipment | 0.5763 | 8.36M | -11.91% | 0.04 | 16.03% |
Forza X1 Inc | FRZA | Recreational Vehicles | 0.2111 | 3.79M | 2.93% | n/a | 0.97% |
EZGO Technologies Ltd. Ordinary Shares | EZGO | Recreational Vehicles | 1.04 | 2.71M | -4.59% | n/a | 9.62% |
Micromobility.com Inc. | MCOM | Recreational Vehicles | 0.0114 | 1.02M | 14.00% | n/a | -37.05% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 60.16 | 0 | -0.43% | n/a | |
Vision Marine Technologies Inc | VMAR | Recreational Vehicles | 4.3 | 0 | 2.14% | n/a | |
Twin Vee PowerCats Co. Common Stock | VEEE | Recreational Vehicles | 0.535 | 0 | 7.00% | n/a | |
Urban One Inc | UONEK | Broadcasting - Radio | 1.07 | 0 | 1.90% | n/a | |
Virco Mfg. Corporation | VIRC | Building Products & Equipment | 14.54 | 0 | -1.56% | n/a |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | 1.14 | 0.53 | Expensive |
Ent. to Revenue | 0.11 | 4,005.99 | Cheaper |
PE Ratio | - | 40.42 | - |
Price to Book | 0.50 | 15.30 | Cheaper |
Dividend Yield | - | 2.20 | - |
Std. Deviation (3M) | 61.38 | 72.92 | Par |
Debt to Equity | 0.55 | -1.24 | Expensive |
Debt to Assets | 0.13 | 0.25 | Cheaper |
Market Cap | 14.08M | 3.78B | Emerging |